Hani Gabra

Hani Gabra

Company: BerGenBio AS

Job title: Chief Medical Officer & Head of Clinical Development


Reprogramming of the Lung Cancer Tumour Microenvironment with the AXL Inhibitor Bemcentinib. 9:50 am

• AXL expression is associated with poor prognosis in NSCLC and drives both aggressive cancer cell biology and innate immune suppression simultaneously • Bemcentinib, a potent and specific, oral AXL kinase inhibitor reverses aggressive cancer cell behaviour and activates innate immunity leading to reengaged anti-tumour cytotoxic T cell responses • Preliminary data from our clinical…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.